NovioSense Announces Successful Clinical Trial and Secures 4th Round Financing for Its Tear Glucose Sensor

Published on:

NIJMEGEN, Netherlands--(BUSINESS WIRE)--Following successful clinical trials in 2015, NovioSense BV, today announced they had closed their 4th financing round for the next clinical validation phase of their smartphone based tear glucose sensor device, to provide an accurate, pain-free and conveniently placed glucose sensor to address the growing diabetes epidemic impacting people’s lives and overwhelming healthcare systems worldwide.

NovioSense has developed a flexible miniature sensor that rests in the lower eyelid and provides glucose measurements directly to a smartphone. NovioSense provides the first of its kind eye-wearable, wireless, battery-free glucose sensor. "Our device will deliver pain-free continuous glucose monitoring to all individuals with diabetes at an affordable price. By utilising NFC technology found in most smartphones, our pain-free non-invasive sensor platform is employed by users to continuously monitor glucose readings, an effective component to any glucose management system," said NovioSense CEO Dr Christopher Wilson

The financing round including existing investors Health Innovations, Topfonds Gelderland, Fraunhofer Ventures and NovioTech along with two new US based investors will build more clinical accuracy data of the sensor platform to compare to competing minimally invasive devices. NovioSense will report its second phase clinical data in the first half 2017 and pursue market clearance in 2019.

As part of the new investment, NovioSense announced Harry G. Mitchell, a senior executive with more than twenty-five years’ experience in medical device, diabetes and related complication spaces joined the company as Executive Vice President of Business Development.

"Through his finance and C-Level experience, Mr. Mitchell is a leading business developer in the medical device and diabetes space, and was recently Co-Founder of Joslin Institute for Technology Translation at the Joslin Diabetes Center in Boston Massachusetts. Throughout his career, Harry has focused on building companies through M&A and publically traded initiatives. We are excited to have Harry on board as we continue to grow and explore several product opportunities using our analyte sensing portfolio." said Dr Wilson.

"I am looking forward to continuing my work with the NovioSense Team and pursuing opportunities to introduce technologies and solutions developed by the Company that will have a commercial impact in Diabetes and related fields in the US and other key markets." said Harry Mitchell.

Related Content

Eko Health’s AI platform for digital stethoscopes granted new CPT code
FDA grants AI-powered ECG screening tool for aortic stenosis its breakthrough device designation
Homemade electrodes made of putty capture heart data as well as some commercial devices
JACC editor excited by progress during a 'very important moment' for cardiology
FDA clears new suite of ECG evaluation tools
PaceMate acquires Medtronic workflow tech, promising ‘unparalleled support’ for heart patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."